Pharmaceutical

Causaly Launches AI-powered Competitive Intelligence Application for Research Scientists

New Pipeline Graph unifies competitive insights with preclinical research on a single AI platform to accelerate drug target identification and…

6 months ago

TAG1 and PharmaLogic Announce Strategic Partnership to Advance Decentralized Lead-212 Generator Development

Collaboration accelerates TAG1's Pb-212 generator development and supports PharmaLogic's mission to scale radiopharmaceutical innovation. ST. LOUIS, June 24, 2025 /PRNewswire/…

6 months ago

MellingMedical Teams Up with Zynex Medical to Expand Access to Non-Invasive Pain Management Solutions Across Federal Healthcare System

Strategic agreement brings innovative electrotherapy and orthotic solutions to America's veterans, active duty and DoD personnel ALEXANDRIA, Va., June 24,…

6 months ago

Mark Hensley joins RBL LLC as a senior adviser

HOUSTON, June 24, 2025 /PRNewswire/ -- RBL LLC, a pioneering biotech venture creation studio designed to rapidly build companies based…

6 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical…

6 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or…

6 months ago

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch…

6 months ago

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer

Enrollment is now underway across multiple clinical sites, in partnership with Syneos HealthVANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) --…

6 months ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced…

6 months ago